R289 for lower-risk MDS that still needs blood support
Part of Blood & lymphatic clinical trials.
This Phase 1/2 study tests R289 in adults with lower-risk myelodysplastic syndromes (MDS) whose disease keeps causing anemia and/or ongoing need for red blood cell transfusions. It may help reduce blood problems and treat MDS when standard options haven’t worked well enough or aren’t suitable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You have a confirmed diagnosis of MDS that is “very low/low/intermediate-1 risk” and you have 5% or fewer blasts in the bone marrow.
- Your MDS must have returned or worsened after prior treatment, or you couldn’t tolerate it, or standard treatments weren’t a good fit for you.
- You have ongoing anemia and either low hemoglobin (under 9) without recent transfusions, or you need red blood cell transfusions regularly.
- Your bone marrow iron level must be documented (or blood tests must show enough iron).
- You must have adequate health for study safety: good activity level (ECOG 0–2) and certain acceptable liver and kidney test results.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an oral form of arsenic in people with low-risk myelodysplastic syndromes (MDS) who need regular red blood cell transfusions and haven't gotten enough benefit from standard treatments. It aims to see if this drug can help reduce transfusion needs.
This study tests a new drug called elritercept for people with myelodysplastic syndromes (MDS) who have low blood counts and need regular blood transfusions. The drug aims to boost red blood cell production and reduce or eliminate the need for transfusions, which can improve energy and quality of life.
This trial tests an investigational drug, TAK-226, for people with lower-risk myelodysplastic syndromes (MDS) who have anemia. The study aims to see if the drug can help improve blood counts and reduce the need for red blood cell transfusions.
This trial is testing whether a combination of two drugs, luspatercept and darbepoetin alfa, can help people with lower-risk myelodysplastic syndromes (MDS) who need frequent red blood cell transfusions. The goal is to see if the combination reduces their need for transfusions.
This Phase 1/2 study tests luspatercept combined with another approach in people with low-risk myelodysplastic syndrome (MDS) who are not responding to or cannot use ESA (a common anemia treatment). It may help improve anemia (low hemoglobin), reduce transfusions, and control the disease if you fit the specific criteria.
This study tests a drug called luspatercept, which helps the body make more red blood cells, in people with low-risk myelodysplastic syndromes (MDS) who have anemia. The goal is to see if it quickly improves blood counts, and you'll track your progress using a smartphone app.
Hear when a new Low Risk Myelodysplastic Syndromes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.